AI in Oncology: New Data Shows Remote Monitoring Cuts Costs, Saves Lives

NEW YORK, NY – May 22, 2026 – By Carol Thomas

Groundbreaking new data suggests that the integration of artificial intelligence into routine cancer care can dramatically reduce hospitalizations, extend the duration of life-sustaining treatments, and save the healthcare system millions of dollars. Two major studies on an AI-powered remote monitoring platform, set to be presented at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, are providing some of the most compelling real-world evidence to date for the transformative potential of digital health in one of medicine's most challenging fields.

The studies focus on the Remote Therapeutic Monitoring (RTM) platform from Canopy, a company specializing in Enterprise AI for oncology. The findings highlight a significant shift in cancer care, moving beyond the traditional model of episodic, in-person visits to one of continuous, proactive support for patients at home. This approach appears to be paying significant dividends for patients, providers, and the healthcare system alike.

A New Paradigm in Proactive Cancer Care

For decades, the standard of cancer care has revolved around scheduled appointments and treatments in a clinical setting, leaving patients to manage complex symptoms and side effects on their own between visits. This gap in care can lead to severe adverse events, emergency room visits, and hospitalizations that are often preventable. Remote Therapeutic Monitoring aims to close that gap. By using digital tools, often on a patient's own smartphone, RTM platforms allow care teams to track patient-reported outcomes (PROs)—such as pain, nausea, or fatigue—in near real-time.

Canopy's platform leverages AI to not only collect this data but also to analyze it, identifying patients at high risk and flagging concerning symptoms before they escalate into crises. This allows nurses and physicians to intervene earlier and more effectively. The upcoming presentations at the ASCO meeting, a premier global event for oncology professionals, lend significant weight to this model's efficacy.

The first study, selected for a high-profile oral presentation, examined 1,549 patients with metastatic solid tumors. It found that patients actively using the Canopy RTM platform experienced a 28% reduction in hospitalizations. The impact was even more profound among the highest-risk patients, who saw hospitalizations drop by nearly half compared to their peers not using the platform.

"These findings add to growing evidence supporting the role of remote therapeutic monitoring in outpatient cancer care," said Dr. James Essell, a respected oncologist and presenting author of the study. "Particularly among high-risk patients receiving systemic therapy, Canopy RTM may help meaningfully reduce hospitalizations and associated acute care costs."

Extending Treatment and Improving Outcomes

The second study, which will be featured in a poster presentation, focused on a particularly challenging area of modern oncology: immunotherapy. While immune checkpoint inhibitors (ICIs) have revolutionized treatment for many cancers, they can also cause a unique and sometimes severe set of side effects. Managing these immune-related adverse events is critical to keeping patients on therapy.

This study of 1,598 patients on ICI therapy found that the RTM platform was associated with a remarkable 79% longer median time on treatment—224 days versus 125 days for the control group. Patients were able to stay on their potentially life-extending therapies longer because their symptoms were being identified and managed more effectively in an outpatient setting. This was supported by data showing a 64% increase in the use of outpatient steroids, a key treatment for managing immune-related side effects, suggesting that clinicians were able to intervene earlier and prevent the need for hospitalization. The result was a 51% reduction in reported hospitalizations at the 12-month mark.

"What stands out in this study is the higher detection of potential immune-related symptoms through the Canopy RTM platform," noted Dr. Benjamin Derman, Assistant Professor of Medicine at the University of Chicago Medicine and the study's presenting author. He explained that the combination of better symptom detection, increased outpatient management, and reduced hospitalizations suggests that RTM can be a powerful tool for managing the complexities of modern cancer therapies.

The Multi-Million Dollar Impact of Remote Care

Beyond the clear clinical benefits, the financial implications of Canopy's findings are staggering. The study on metastatic solid tumor patients estimated an annualized savings of approximately $3.1 million for every 1,000 patients treated. The savings were even more dramatic in the immunotherapy study, which projected an estimated $12.6 million in annualized acute-care cost savings per 1,000 patients.

These figures highlight a crucial value proposition for a healthcare system grappling with the escalating costs of cancer care. By preventing costly emergency room visits and inpatient stays, RTM platforms offer a pathway to a more sustainable financial model. This shift is being recognized and encouraged by policymakers. The Centers for Medicare & Medicaid Services (CMS) has been progressively updating its billing codes, and for 2026, it has introduced more flexible rules for RTM. These changes make it more financially viable for oncology practices to adopt and get reimbursed for remote monitoring, signaling long-term support for this model of care.

Navigating the Path to Widespread Adoption

Despite the compelling evidence, the road to widespread implementation of RTM in oncology is not without its challenges. Integrating new technology into the complex and often overburdened workflows of a busy cancer clinic requires careful planning. Staff training, ensuring seamless integration with existing electronic health records (EHRs), and managing the sheer volume of incoming patient data are significant operational hurdles.

Furthermore, patient-side barriers such as digital literacy, access to technology, and reliable internet connectivity must be addressed to ensure equitable access to these benefits. Successful implementation hinges on provider buy-in and platforms that are intuitive for both clinicians and patients. Companies in this space, including competitors like Reimagine Care and Navigating Care, are all working to solve these real-world challenges by offering more unified, user-friendly solutions and managed services that reduce the burden on clinic staff.

The data being presented by Canopy at ASCO represents a significant milestone, moving the conversation about RTM from theoretical potential to proven, quantifiable impact. As AI and digital health tools become more sophisticated and integrated into clinical practice, they promise to make cancer care more proactive, personalized, and sustainable for everyone involved.